- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03289208
Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Renal Impairment
April 3, 2023 updated by: Mitsubishi Tanabe Pharma America
An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of MCI-186 in Subjects With Mild or Moderate Renal Impairment Compared to Subjects With Normal Renal Function
To assess the pharmacokinetics of MCI-186 after a single intravenous infusion of 30mg/hour in subjects with mild or moderate renal impairment compared to subjects with normal renal function.
Study Overview
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tokyo, Japan
- Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
All subjects
- Able to provide written informed consent to participate in this study after reading the ICF
- Subjects is able to understand and willing to cooperate and comply with the Protocol restrictions and requirements
- A body weight of ≥45 kg in males or ≥40 kg in females and a body mass index ranging from 18 to 30 kg/m2
Renal impaired subjects (in addition)
- Subjects with mild renal impairment defined as eGFR 60-89 mL/min/1.73m2 and subjects with moderate renal impairment defined as eGFR 30-59 mL/min/1.73m2
- Chronic and stable renal impairment
Healthy subjects (in addition)
- Subject with normal renal function defined as eGFR≥90 mL/min/1.73m2
- Good health and free from clinically significant illness or disease
Exclusion Criteria:
All subjects
- Presence or history of severe allergy to food, or any medicinal product or relevant excipient that is of clinical significance
- Subjects were previously administered MCI-186
- Positive urine drug screen (if not due to concomitant medication) or alcohol test
- History of alcohol abuse or drug abuse
- Presence of active infection requiring antibiotics
- Positive test for human immunodeficiency virus (HIV) antigen/antibody, hepatitis B surface antigen (HBsAg), or hepatitis C virus antibody (HCVAb)
Renal impairment subject (in addition)
- Acute renal failure
- History of renal transplantation
- Aspartate aminotransferase (AST) activity, or an alanine aminotransferase (ALT) activity of at least 3 times the upper limit of normal (ULN) range
- Uncontrolled, or untreated hypertension defined as systolic blood pressure (SBP)>180 mmHg and/or diastolic blood pressure (DBP)>110 mmHg
- Start of any new medication or new any changes to a current dosage
Healthy subject (in addition)
- History or presence of any renal disease
- Uncontrolled, or untreated hypertension defined as systolic blood pressure (SBP)>160 mmHg and/or diastolic blood pressure (DBP)>100 mmHg
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: mild renal impairment
|
30 mg of edaravone will be administered intravenously over 60 minutes.
Other Names:
|
Experimental: moderated renal impairment
|
30 mg of edaravone will be administered intravenously over 60 minutes.
Other Names:
|
Experimental: normal renal function
|
30 mg of edaravone will be administered intravenously over 60 minutes.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cmax
Time Frame: pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h post-dose
|
pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h post-dose
|
AUC0-last
Time Frame: pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h post-dose
|
pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h post-dose
|
AUC0-∞
Time Frame: pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h post-dose
|
pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h post-dose
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
t½
Time Frame: pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h post-dose
|
pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h and 48h post-dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: General Manager, Mitsubishi Tanabe Pharma America
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 27, 2016
Primary Completion (Actual)
April 16, 2018
Study Completion (Actual)
April 20, 2018
Study Registration Dates
First Submitted
September 19, 2017
First Submitted That Met QC Criteria
September 19, 2017
First Posted (Actual)
September 20, 2017
Study Record Updates
Last Update Posted (Actual)
April 5, 2023
Last Update Submitted That Met QC Criteria
April 3, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MCI-186-J22
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on MCI-186
-
Mitsubishi Tanabe Pharma CorporationTerminated
-
Mitsubishi Tanabe Pharma CorporationCompletedAmyotrophic Lateral Sclerosis (ALS)
-
Mitsubishi Tanabe Pharma CorporationCompletedAmyotrophic Lateral Sclerosis (ALS)
-
Mitsubishi Tanabe Pharma CorporationCompletedAmyotrophic Lateral Sclerosis (ALS)Japan
-
Mitsubishi Tanabe Pharma CorporationCompletedAmyotrophic Lateral Sclerosis (ALS)Japan
-
Mitsubishi Tanabe Pharma CorporationCompletedAcute Ischemic Stroke (AIS)Netherlands, Finland, United Kingdom
-
Mitsubishi Tanabe Pharma AmericaCompletedHealthy | Hepatic ImpairmentJapan
-
Mitsubishi Tanabe Pharma CorporationCompleted
-
Mitsubishi Tanabe Pharma CorporationCompletedHealthy Adult SubjectsJapan
-
Mitsubishi Tanabe Pharma CorporationCompletedHealthy | Severe Hepatic ImpairmentCzechia, Hungary, Slovakia